Has COVID-19 specifically reduced Interviewing for vacant MSL positions? Has COVID-19 specifically reduced Hiring new MSLs for your team?

An important aspect of this survey was to capture how the COVID-19 international pandemic has impacted interviewing and hiring of MSLs during an early phase (March 24-30, 2020). These survey questions captured the feedback from MSL Managers and Executives based on responses to 2 key questions:

Has COVID-19 specifically reduced Interviewing for vacant MSL positions?
Has COVID-19 specifically reduced hiring new MSLs for your team?

When reviewing the survey results as they relate to the impact on interviewing for vacant MSL positions, we included both global and US results. To provide relevant trends, we looked at percentages and broke the results out into categories focusing on those with sizable response rates (per the survey questions there were several other categories that are not included here due to response rate significance). The size/type of the company seemed to illustrate the clearest delineations. We will highlight:

Large Pharmaceuticals (Revenue of $10+Billion USD)
Medium Pharmaceuticals (Revenue of $1-10 Billion USD)
Small Pharmaceuticals (Revenue of Less than 1 Billion USD)
Biotechnology

Below tables illustrate that Covid-19 impacts small pharma interviewing most significantly. There are a plethora of reasons for this, and initial analysis would imply that size and capital would be a key factor, however we did not address those in the survey. While medium pharma results are listed globally, the impact of Covid-19 did not present a dramatic difference at the time of this survey.

Global

U.S.

We also looked at the reported reduction of hiring of MSLs.

Global U.S.

When reviewing the survey results as they relate to the impact on hiring for vacant MSL positions, again the tables illustrate that Covid-19 impacts small pharma hiring most significantly. There are a plethora of reasons for this, however we did not address them in this survey. Medium pharma results are again listed globally; impact of Covid-19 did not present a dramatic difference.